tiprankstipranks
Advertisement
Advertisement

DE:9IP1 Stock Latest News

Rocket Pharmaceuticals price target raised to $9 from $8 at BofA
The FlyRocket Pharmaceuticals price target raised to $9 from $8 at BofA
13d ago
RCKT
Balancing Early Gene Therapy Validation Against Limited Near-Term Revenue and Pipeline Risk: Rationale for Maintaining a Hold on Rocket
PremiumRatings
Balancing Early Gene Therapy Validation Against Limited Near-Term Revenue and Pipeline Risk: Rationale for Maintaining a Hold on Rocket
13d ago
RCKT
Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink
PremiumThe Fly
Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink
15d ago
RCKT
PRV reception could net Rocket $100M-$200M, says LifeSci Capital
PremiumThe Fly
PRV reception could net Rocket $100M-$200M, says LifeSci Capital
15d ago
RCKT
Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush
PremiumThe Fly
Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush
15d ago
RCKT
Rocket Pharmaceuticals: FDA Validation, Non-Dilutive Funding Catalyst, and Pipeline De-Risking Support Buy Rating
PremiumRatingsRocket Pharmaceuticals: FDA Validation, Non-Dilutive Funding Catalyst, and Pipeline De-Risking Support Buy Rating
15d ago
RCKT
Rocket Pharmaceuticals: Kresladi Approval, Non‑Dilutive Capital, and Danon Pipeline Progress Underscore Buy Rating Despite Share Weakness
Premium
Ratings
Rocket Pharmaceuticals: Kresladi Approval, Non‑Dilutive Capital, and Danon Pipeline Progress Underscore Buy Rating Despite Share Weakness
15d ago
RCKT
Rocket Pharmaceuticals: First Approval and Extended Cash Runway Offset by Long Path to Meaningful Kresladi Revenues, Warranting a Hold Rating
Premium
Ratings
Rocket Pharmaceuticals: First Approval and Extended Cash Runway Offset by Long Path to Meaningful Kresladi Revenues, Warranting a Hold Rating
15d ago
RCKT
Video: Unity rises after better-than-expected pre-announcement
PremiumThe Fly
Video: Unity rises after better-than-expected pre-announcement
15d ago
U
AGX
Rocket Pharmaceuticals wins FDA nod for KRESLADI gene therapy
PremiumCompany Announcements
Rocket Pharmaceuticals wins FDA nod for KRESLADI gene therapy
15d ago
8K
RCKT
Rocket Pharmaceuticals announces FDA approval of Kresladi
PremiumThe Fly
Rocket Pharmaceuticals announces FDA approval of Kresladi
16d ago
RCKT
Rocket Pharmaceuticals: FDA Approval of Kresladi Marks Strategic Inflection Point Supporting Buy Rating
PremiumRatings
Rocket Pharmaceuticals: FDA Approval of Kresladi Marks Strategic Inflection Point Supporting Buy Rating
16d ago
RCKT
FDA approves Rocket Pharmaceuticals’ Kresladi in LAD-I
PremiumThe FlyFDA approves Rocket Pharmaceuticals’ Kresladi in LAD-I
16d ago
RCKT
Rocket Pharmaceuticals Launches New $100M At-The-Market Program
Premium
Company Announcements
Rocket Pharmaceuticals Launches New $100M At-The-Market Program
1M ago
8K
RCKT
Rocket Pharmaceuticals offers to sell up to $100M in common stock
Premium
The Fly
Rocket Pharmaceuticals offers to sell up to $100M in common stock
1M ago
RCKT
Rocket Pharmaceuticals files $400M mixed securities shelf
PremiumThe Fly
Rocket Pharmaceuticals files $400M mixed securities shelf
1M ago
RCKT
Rocket Pharmaceuticals price target raised to $3 from $2 at Goldman Sachs
PremiumThe Fly
Rocket Pharmaceuticals price target raised to $3 from $2 at Goldman Sachs
1M ago
RCKT
Midday Fly By: Paramount wins Warner bidding, Amazon to invest $5oB in OpenAI
PremiumThe Fly
Midday Fly By: Paramount wins Warner bidding, Amazon to invest $5oB in OpenAI
1M ago
BCO
CRI
Rocket Pharmaceuticals price target raised to $10 from $8 at Cantor Fitzgerald
PremiumThe Fly
Rocket Pharmaceuticals price target raised to $10 from $8 at Cantor Fitzgerald
1M ago
RCKT
Rocket Pharmaceuticals: Advancing Gene Therapy Pipeline and High-Confidence KRESLADI Approval Drive Buy Rating
PremiumRatingsRocket Pharmaceuticals: Advancing Gene Therapy Pipeline and High-Confidence KRESLADI Approval Drive Buy Rating
1M ago
RCKT
Balanced View on RCKT: Clinical Progress Offsetting Execution and Regulatory Risks Supports Hold Rating
Premium
Ratings
Balanced View on RCKT: Clinical Progress Offsetting Execution and Regulatory Risks Supports Hold Rating
1M ago
RCKT
Rocket Pharmaceuticals reports Q4 EPS (38c), consensus (42c)
Premium
The Fly
Rocket Pharmaceuticals reports Q4 EPS (38c), consensus (42c)
1M ago
RCKT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >